Trial Profile

The effect of SGLT2 inhibitor tofogliflozin on glycemic daily variation by blood glucose using CGMs in patient with type 2 diabetes.

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 20 Aug 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tofogliflozin (Primary)
Indications Type 2 diabetes mellitus
Focus Therapeutic Use

Most Recent Events

13 Aug 2021 Results (n=17) assessing acute effects of add- on therapy with the sodium glucose co- transporter 2 inhibitor tofogliflozin to dipeptidyl peptidase (DPP)- 4 inhibitors on 24- hours glucose profile and glycaemic variability evaluated by continuous glucose monitoring (CGM) in patients with type 2 diabetes, published in the International Journal of Clinical Practice.
29 Dec 2016 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com